NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/29/2024
Back to search
Official data from USPTO
NIPD GENETICS TARCET IVD KIT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/29/2024
Classification
Registered
Trademark type
Combined
Nice classes
1, 5
Filing date
11/30/2021
Registration date
06/13/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/13/2023
Last transaction
04/29/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CY
Examiner
LAPTER, ALAIN
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording NIPD GENETICS in grey above the term TARCET in grey with a lighter grey "C" within the letter larger "C" in TARCET and with a yellow dot inside the smaller "C". Below appears the wording IVD KIT in grey.
Holders and representatives
Holders
MEDICOVER BIOTECH LTD
Representatives
Paulo A. de Almeida Patel & Almeida, P.C.
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Kits composed of reagents for genetic testing for medical and scientific research purposes; nucleic acid-based kits and reagents for genetic testing for medical and scientific research purposes
Class 5
Reagents for medical use; diagnostic reagents for medicinal use; reagents for use in medical genetic testing; medical diagnostic reagents; nucleic acid sequences for medical purposes
Publications
History of USPTO decisions and trademark events.
29 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/28/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/30/2023
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
10/10/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/14/2023
FIMP
FINAL DISPOSITION PROCESSED
09/14/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/13/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/13/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2023
GPNX
NOTIFICATION PROCESSED BY IB
03/29/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/28/2023
PUBO
PUBLISHED FOR OPPOSITION
03/28/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/16/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/15/2023
RFNT
REFUSAL PROCESSED BY IB
12/05/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/16/2022
RFRR
REFUSAL PROCESSED BY MPU
11/16/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/07/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/13/2022
CNRT
NON-FINAL ACTION WRITTEN
09/12/2022
DOCK
ASSIGNED TO EXAMINER
09/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/25/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/21/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/20/2022
Continuous trademark protection
Get notified about every new filing that threatens NIPD GENETICS TARCET IVD KIT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.